Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
rhIL-1Ra Ophthalmic Solution in Mild to Moderate BKC
CTR20190487Phase 2Active
- Sponsor
- Tibet Huaxi Pharmaceutical Group
- Start
- Apr 2019
- Modality
- Cytokines & Interferons → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 2 trial of anakinra in blepharokeratoconjunctivitis (BKC), sponsored by Tibet Huaxi Pharmaceutical Group. Started Apr 2019; status: active.
02
Drugs
anakinra
03
Conditions
blepharokeratoconjunctivitis (BKC)
Beyond the preview
Go deeper on CTR20190487.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20190487.